Malignant neoplasm of lung
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
SWOG S1400B (NCT02785913), a Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K-Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study).
|
31158500 |
2019 |
Malignant neoplasm of lung
|
0.600 |
Biomarker
|
disease |
BEFREE |
All of these results suggested that the lncRNA FER1L4 suppressed cell proliferation and metastasis by inhibiting the PI3K/Akt signaling pathway in lung cancer.
|
31115514 |
2019 |
Malignant neoplasm of lung
|
0.600 |
Biomarker
|
disease |
BEFREE |
Co-mutations in <i>TP53</i> and the <i>PI3K/AKT/mTOR</i> pathway confer additional resistance to anti-HER2 treatments in lung cancer.
|
31748336 |
2019 |
Malignant neoplasm of lung
|
0.600 |
Biomarker
|
disease |
BEFREE |
Long non-coding RNA OECC promotes cell proliferation and metastasis through the PI3K/Akt/mTOR signaling pathway in human lung cancer.
|
31452780 |
2019 |
Malignant neoplasm of lung
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Consistently, DOK7V1 overexpression in lung cancer cells suppressed the phosphoinositide 3‑kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR) signaling pathways, but activated the focal adhesion kinase (FAK)/paxillin signaling pathway.
|
30431081 |
2019 |
Malignant neoplasm of lung
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Finally, we identified that the PI3K-AKT and epilthelial-mesenchymal transition (EMT) signaling pathways were inhibited by miR-3666 overexpression in lung cancer cells.
|
30481052 |
2019 |
Malignant neoplasm of lung
|
0.600 |
Biomarker
|
disease |
BEFREE |
Furthermore, cotreatment with sesamin and CAY10404 markedly reduced the levels of phosphorylated protein kinase B (pAkt) and phosoinositide 3 kinase (PI3K) in three lung cancer cell lines.
|
30365050 |
2019 |
Malignant neoplasm of lung
|
0.600 |
Biomarker
|
disease |
BEFREE |
Dual molecular targeted therapy for mTOR and PI3K may be a promising therapeutic strategy in the specific population of patients with lung cancer with LKB1 loss.
|
30825612 |
2019 |
Malignant neoplasm of lung
|
0.600 |
Biomarker
|
disease |
BEFREE |
Therefore, targeting the PI3K pathway may be a potential therapeutic strategy that prevents the structural skeletal damage associated with bone metastasis of lung cancer.
|
30896825 |
2019 |
Malignant neoplasm of lung
|
0.600 |
Biomarker
|
disease |
BEFREE |
The phosphoinositide 3-kinase (PI3K)/AKT/mechanistic target of rapamycin (mTOR) signaling has been shown to contribute to tumorigenesis, tumor progression, and resistance to therapy in most human cancer types, including lung cancer.
|
31262325 |
2019 |
Malignant neoplasm of lung
|
0.600 |
Biomarker
|
disease |
BEFREE |
Mutations in EGFR, KRAS, BRAF, and PIK3CA genes are widely analyzed in solid tumors such as lung cancer, colorectal cancer, breast cancer, and melanoma.
|
29304903 |
2019 |
Malignant neoplasm of lung
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
MicroRNA-374b accelerates the development of lung cancer through downregulating PTEN expression via activating PI3K/Akt pathway.
|
30779080 |
2019 |
Malignant neoplasm of lung
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
We performed NF1 sequencing using next generation sequencing (NGS) in 154 lung adenocarcinoma surgical specimens with known KRAS, EGFR, TP53, BRAF, HER2, and PIK3CA status, to evaluate the molecular and clinical specificities of NF1-mutated lung cancers.
|
31199580 |
2019 |
Malignant neoplasm of lung
|
0.600 |
Biomarker
|
disease |
BEFREE |
Our studies suggest that miR-183-5p may function as a tumor suppressor in lung cancer via the miR-183-5p/PIK3CA regulatory axis and identify a potentially effective therapeutic strategy for lung cancer.
|
30528264 |
2019 |
Malignant neoplasm of lung
|
0.600 |
Biomarker
|
disease |
BEFREE |
TP53, EGFR and PIK3CA gene variations observed as prominent biomarkers in breast and lung cancer by plasma cell-free DNA genomic testing.
|
31100334 |
2019 |
Malignant neoplasm of lung
|
0.600 |
Biomarker
|
disease |
BEFREE |
Inotilone from Inonotus linteus suppresses lung cancer metastasis in vitro and in vivo through ROS-mediated PI3K/AKT/MAPK signaling pathways.
|
30787353 |
2019 |
Malignant neoplasm of lung
|
0.600 |
Biomarker
|
disease |
BEFREE |
Additionally, Aclidinium Bromide suppressed the PI3K/AKT signaling pathway in lung cancer A549 cells.
|
31128006 |
2019 |
Malignant neoplasm of lung
|
0.600 |
Biomarker
|
disease |
BEFREE |
To date, PI3K inhibitors have not been approved for lung cancer.
|
31337981 |
2019 |
Malignant neoplasm of lung
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Compared with those in the control group, expression of PI3K and Akt in the lung cancer cells H1299 after EGCG treatment showed no significant differences (p>0.05), while expression levels of p-PI3K and p-Akt were significantly reduced (p<0.05).
|
30058690 |
2018 |
Malignant neoplasm of lung
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Cisplatin resistance in lung cancer is mediated by MACC1 expression through PI3K/AKT signaling pathway activation.
|
29961813 |
2018 |
Malignant neoplasm of lung
|
0.600 |
Biomarker
|
disease |
BEFREE |
Moreover, MCMs and PHGDH can be poor prognostic factors for lung cancer.
|
29888431 |
2018 |
Malignant neoplasm of lung
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
IFN-γ-mediated inhibition of lung cancer correlates with PD-L1 expression and is regulated by PI3K-AKT signaling.
|
29516506 |
2018 |
Malignant neoplasm of lung
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
We demonstrated that regulation of JNK/ P38/PI3K by TGF-β1 led to down expression of NMII-A which promoted EMT and lung cancer metastasis.
|
28782471 |
2018 |
Malignant neoplasm of lung
|
0.600 |
Biomarker
|
disease |
BEFREE |
The effect of paclitaxel combined with lobaplatin on the sensitivity of lung cancer cell line NCI-H446 through influencing the phosphatidylinositol 3-kinase (PI3K)/Akt pathway was investigated.
|
29616103 |
2018 |
Malignant neoplasm of lung
|
0.600 |
Biomarker
|
disease |
BEFREE |
Effect of miR-21 on Apoptosis in Lung Cancer Cell Through Inhibiting the PI3K/ Akt/NF-κB Signaling Pathway in Vitro and in Vivo.
|
29669316 |
2018 |